Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 22, 2022 - Issue 4
Submit an article Journal homepage
235
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia

Jefferson Antonio Buendíaa Research Group in Pharmacology and Toxicology ”Infarto”. Department of Pharmacology and Toxicology. University of Antioquia, Universidad de Antioquia, Medellín, ColombiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-2404-6612
ORCID Icon &
Diana Guerrero Patiñob Deparment of Child Health, Hospital Infantil Concejo de Medellín, Colombia
Pages 575-580 | Received 07 Aug 2021, Accepted 23 Nov 2021, Published online: 03 Dec 2021

References

  • Collaborators GBDCRD. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596.
  • Asher MI, Garcia-Marcos L, Pearce NE, et al. Trends in worldwide asthma prevalence. Eur Respir J. 2020;56(6). https://doi.org/10.1183/13993003.02094-2020
  • Hekking PW, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902.
  • Yaghoubi M, Adibi A, Safari A, et al. The Projected Economic and Health Burden of Uncontrolled Asthma in the United States. Am J Respir Crit Care Med. 2019;200(9):1102–1112.
  • Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023–1042.
  • Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.
  • Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018;378(26):2486–2496.
  • Salud. IdETe. Manual metodológico para la elaboración de evaluaciones de efectividad, seguridad y validez diagnóstica de tecnologías en salud. 2014.
  • Einarson TR, Bereza BG, Nielsen TA, et al. Utilities for asthma and COPD according to category of severity: a comprehensive literature review. J Med Econ. 2015;18(7):550–563.
  • Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim Care Respir J. 2007;16(1):22–27.
  • Neffen H, Moraes F, Viana K, et al. Asthma severity in four countries of Latin America. BMC Pulm Med. 2019;19(1):123.
  • Husereau D, Drummond M, Petrou S, et al. consolidated health economic evaluation reporting standards (CHEERS) statement. Value Health. 2013;16(2):e1–5.
  • Caminati M, Senna G, Stefanizzi G, et al. Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience. BMC Pulm Med. 2016;16(1):128.
  • Florez-Tanus A, Parra D, Zakzuk J, et al. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. World Allergy Organ J. 2018;11(1):26.
  • (DANE) DNdE. Archivo nacional de datos 2019 [cited 2021 Nov 29]. Available from: https://sitios.dane.gov.co/anda-index/.
  • Dennis RJ, Caraballo L, Garcia E, et al. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study. BMC Pulm Med. 2012;12(1):17.
  • Excellence NIfHaC. Single Technology Appraisal Dupilumab for treating severe asthma [ID1213] [cited 2021 Nov 29]. Available from: https://www.nice.org.uk/guidance/indevelopment/gid-ta10276.
  • Agache I, Rocha C, Pereira A, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: a systematic review for the EAACI Biologicals Guidelines. Allergy. 2021;76(1):59–70.
  • Asthma GIf. Global strategy for ashtma management and prevention 2021 [cited 2021 May 06]. Available from: https://ginasthma.org/.
  • Sanchez J, Morales E, Santamaria LC, et al. IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma. World Allergy Organ J. 2021;14(3):100520.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.